Bone Health represent a considerable health challenge around the world. Globally, osteoporosis causes more than 8.9 million fractures annually, with the disease affecting approximately 21.2% of women and 6.3% of men aged over 50.1 Across 29 European countries, the direct cost of osteoporotic fractures in 2019 has been calculated at €56.9 billion.2
STADA contributes to managing both the disease burden and the resulting costs through bringing competition to the biologic medicines market in Europe. This medicine for post-menopausal women and men at increased risk of fractures is administered with a reusable pen injector, assisting patients in managing their own health.
